B Riley Principal 250 Merger Corp (BRIV) Peer Comparison
$10.19
$0.00 (0.00%)As on 12-May-2023 09:30EDT
Market cap
$226 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
40.7
P/B Ratio
1.3
Div. Yield
0 %
Edit
| B Riley Principal 250 Merger Corp (BRIV) | Kimbell Tiger Acquisition Corp (TGR-UN) | Kimbell Tiger Acquisition Corp (TGR) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|---|
Market cap ($ Mln) |
226 | -- | 303 | 259 | 65 |
Revenue ($ Mln) |
-- | -- | -- | -- | -- |
Net Profit ($ Mln) |
5.58 | 5.20 | 3.88 | 9.88 | 9.88 |
Net Margin (%) |
105.83 | -- | 100.65 | 114.93 | 114.93 |
RoE (%) |
3.21 | 2.18 | 1.69 | 4.91 | 4.91 |
Price to Earnings |
40.74 | -- | 263.75 | -- | 23.00 |
Price-To-Book |
1.27 | -- | -- | -- | -- |
Income Statement ($ Mln)
| B Riley Principal 250 Merger Corp (BRIV) | Kimbell Tiger Acquisition Corp (TGR-UN) | Kimbell Tiger Acquisition Corp (TGR) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|---|
|
Operating Revenue
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Cost of Revenue
|
1.18 | -- | -- | -- | -- |
|
Gross Profit
|
-1.18 | -- | -- | -- | -- |
|
Operating Expenses
|
1.18 | 2.30 | 2.30 | 1.28 | 1.28 |
|
Operating Profit (EBIT)
|
-1.18 | -2.30 | -2.30 | -14.54 | -14.54 |
|
Other Income
|
7.07 | -- | 3.72 | 13.26 | 13.26 |
|
Profit before Tax
|
5.89 | 1.42 | 1.42 | 11.97 | 11.97 |
|
Provision for Tax
|
0.45 | 0.21 | 0.21 | 0.56 | 0.56 |
|
Profit after Tax (Net Income)
|
5.44 | 1.16 | 1.16 | 11.41 | 11.41 |
|
Minority Interest
|
-- | -- | 0.04 | -- | -- |
|
Consolidated Profit
|
5.44 | -- | 1.16 | 11.41 | 11.41 |
Liabilities ($ Mln)
| B Riley Principal 250 Merger Corp (BRIV) | Kimbell Tiger Acquisition Corp (TGR-UN) | Kimbell Tiger Acquisition Corp (TGR) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|---|
|
Shareholder's Funds
|
174.61 | 231.78 | 231.78 | 202.40 | 202.40 |
|
Minority Interest
|
-- | -- | 0.04 | -- | -- |
|
Non-Current Liabilities
|
0.18 | 0.24 | 0.24 | 10.56 | 10.56 |
|
Current Liabilities
|
0.81 | 9.23 | 9.23 | 1.08 | 1.08 |
|
Total Liabilities
|
175.60 | 241.05 | 241.05 | 214.03 | 214.03 |
Assets ($ Mln)
| B Riley Principal 250 Merger Corp (BRIV) | Kimbell Tiger Acquisition Corp (TGR-UN) | Kimbell Tiger Acquisition Corp (TGR) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|---|
|
Non-Current Assets
|
174.44 | 0.00 | 0.00 | 213.85 | 213.85 |
|
Current Assets
|
1.16 | 241.05 | 241.05 | 0.19 | 0.19 |
|
Total Assets
|
175.60 | 241.05 | 241.05 | 214.03 | 214.03 |
|
Total Debt*
|
-- | -- | -- | -- | -- |
|
Net Current Assets
|
0.35 | 231.82 | 231.82 | -0.89 | -0.89 |
Cashflow ($ Mln)
| B Riley Principal 250 Merger Corp (BRIV) | Kimbell Tiger Acquisition Corp (TGR-UN) | Kimbell Tiger Acquisition Corp (TGR) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|---|
|
Cash From Operating Activities
|
-0.61 | -1.76 | -1.76 | -0.87 | -0.87 |
|
Cash Flow from Investing Activities
|
-172.50 | -- | -236.90 | 0.34 | 0.34 |
|
Cash from Financing Activities
|
0.00 | 239.02 | 239.02 | -0.01 | -0.01 |
|
Net Cash Inflow / Outflow
|
-0.61 | -- | 0.36 | -0.54 | -0.54 |
Ratios
Profitability Ratios
| B Riley Principal 250 Merger Corp (BRIV) | Kimbell Tiger Acquisition Corp (TGR-UN) | Kimbell Tiger Acquisition Corp (TGR) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|---|
|
ROCE (%)
|
3.16 | 1.00 | 1.00 | 5.80 | 5.80 |
|
ROE (%)
|
3.16 | 1.00 | 1.00 | 5.80 | 5.80 |
|
ROA (%)
|
3.11 | 0.96 | 0.96 | 5.36 | 5.36 |
|
EBIT Margin (%)
|
-- | -- | -- | -- | -- |
|
Net Margin (%)
|
76.89 | -- | 31.07 | 86.07 | 86.07 |
|
Cash Profit Margin (%)
|
-- | -- | -- | -- | -- |
Growth Ratios
| B Riley Principal 250 Merger Corp (BRIV) | Kimbell Tiger Acquisition Corp (TGR-UN) | Kimbell Tiger Acquisition Corp (TGR) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|---|
|
Revenue Growth (%)
|
-- | -- | -- | -- | -- |
|
EBIT Growth (%)
|
-- | -- | -- | -- | -- |
|
Net Profit Growth (%)
|
499.36 | 409.41 | 409.41 | -- | -- |
|
EPS Growth (%)
|
4.99 | 4.09 | -- | -- | -- |
|
Book Value Growth (%)
|
-- | -- | -- | -- | -- |
Valuation Ratios
| B Riley Principal 250 Merger Corp (BRIV) | Kimbell Tiger Acquisition Corp (TGR-UN) | Kimbell Tiger Acquisition Corp (TGR) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|---|
|
Price / Earnings
|
7.32 | 116.04 | -- | 23.25 | -- |
|
Price / Book Value
|
0.23 | 0.58 | -- | 1.31 | -- |
|
Dividend Yield (%)
|
-- | -- | -- | -- | -- |
|
EV/EBITDA
|
-6.83 | 98.03 | -- | -- | -- |
|
Market Cap ($ Cr)
|
-- | -- | -- | -- | -- |
Solvency Ratios
| B Riley Principal 250 Merger Corp (BRIV) | Kimbell Tiger Acquisition Corp (TGR-UN) | Kimbell Tiger Acquisition Corp (TGR) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|---|
|
Debt to Equity
|
-- | -- | -- | -- | -- |
|
Short term debt to equity ratio
|
0.00 | -- | 0.00 | -- | -- |
|
Current Ratio
|
1.43 | 26.13 | 26.13 | 0.17 | 0.17 |
|
Quick Ratio
|
-- | -- | -- | -- | -- |
|
Interest Coverage
|
-0.17 | -0.63 | -0.63 | -0.55 | -0.55 |
Operating Efficiency Ratios
| B Riley Principal 250 Merger Corp (BRIV) | Kimbell Tiger Acquisition Corp (TGR-UN) | Kimbell Tiger Acquisition Corp (TGR) | Intelligent Medicine Acquisition Corp Unit (IQMDU) | Intelligent Medicine Acquisition Corp (IQMD) | |
|---|---|---|---|---|---|
|
Debtors to sales (%)
|
-- | -- | -- | -- | -- |
|
Asset Turnover
|
0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
|
Receivable days
|
-- | -- | -- | -- | -- |
|
Inventory Days
|
-- | -- | -- | -- | -- |
|
Payable days
|
71.34 | -- | -- | -- | -- |
|
Cash Conversion Cycle
|
-- | -- | -- | -- | -- |
*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.
loading...
loading...
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
